Erythropoietin and Magnesium Sulphate in Hypoxic Ischaemic Encelpalopathy
Not Applicable
Not yet recruiting
- Conditions
- Neonatal DiseasesPregnancy and Childbirth
- Registration Number
- PACTR201812814507775
- Lead Sponsor
- Ezenwa Beatrice
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
All term newborns (= 37weeks gestation) diagnosed of perinatal asphyxia at admission and who are <72 hours of age.
Evidence of Perinatal depression based on delayed cry at birth and at least one criteria on Sarnat and Sarnat HIE grading
Exclusion Criteria
Severe congenital anomalies
Preterm babies
Infants >72 hours of age at time of presentation /consent
Those in which consent could not be obtained
Evidence of sepsis (confirmed according to unit protocol)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Erythropoietin's neuroprotective effects in Hypoxic Ischaemic Encephalopathy?
How does Magnesium Sulphate compare to standard-of-care therapies in perinatal asphyxia treatment outcomes?
Which biomarkers are associated with improved response to Erythropoietin and Magnesium Sulphate in neonatal brain injury?
What are the potential adverse events of combined Erythropoietin and Magnesium Sulphate therapy in neonates?
Are there synergistic effects when combining Erythropoietin with other neuroprotectants for Hypoxic Ischaemic Encephalopathy?